Skip to main content

Advertisement

Table 1 Patient characteristics by treatment type

From: The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients

  Chemotherapy (n = 57) erlotinib (n = 70) p value
Age
 Mean (SD) 64.0 (8.9) 64.0 (9.7) 0.9960
 Median (Range) 65.1 (44.2–83.7) 64.5 (40.9–88.2) 0.8383
VeriStrat Classification, n (%) 0.6865
 Good 41 (71.9) 53 (75.7)  
 Poor 16 (28.1) 17 (24.3)  
Gender, n (%) 0.4800
 Female 28 (49.2) 39 (55.7)  
 Male 29 (50.9) 31 (44.3)  
Race 0.2711
 White 40 (70.2) 52 (74.3)  
 Black 16 (28.1) 15 (21.4)  
 Asian/Pacific Islander 0 (0) 3 (4.3)  
 Asian 1 (1.8) 0 (0)  
Histology, n (%) 0.1845
 Adenocarcinoma 34 (59.6) 46 (65.7)  
 Adenosquamous 2 (3.5) 0 (0)  
 Bronchioalveolar 0 (0) 1 (1.4)  
 Bronchogenic carcinoma 1 (1.8) 0 (0)  
 Carcinoma 6 (10.5) 9 (12.9)  
 Large Cell 0 (0) 1 (1.4)  
 NSCLC 3 (5.3) 0 (0)  
 Neuroendocrine 1 (1.8) 0 (0)  
 Squamous 10 (17.5) 13 (18.6)  
Smoking Status, n (%) 0.0831
 Yes 52 (91.2) 58 (82.9)  
 No 4 (7.0) 12 (17.1)  
 Missing 1 (1.8) 0 (0)  
Performance Status, n (%) 0.6697
 0 12 (21.1) 16 (22.9)  
 0.5 1 (1.8) 0 (0)  
 1 35 (61.4) 45 (64.3)  
 1.5 1 (1.8) 1 (1.4)  
 2 8 (13.1) 6 (8.6)  
 3 0 (0) 2 (2.9)  
Grade n (%) 0.4455
 Moderately 6 (10.5) 10 (14.3)  
 Moderately/Poorly 2 (3.5) 3 (4.3)  
 Nos 26 (45.6) 26 (37.1)  
 Poorly 21 (36.8) 25 (35.7)  
 Well 1 (1.8) 6 (8.6)  
 Well/Moderately 1 (1.8) 0 (0)